Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
NCT04480450
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Unable to acquire funding
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
DRUG:
Rituximab
Sponsor
University of Kansas Medical Center